Indian Journal of Public Health Research & Development

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Prevalence of BCR/ABL Fusion Gene Expression in Acute Myeloid Leukemia Patients: A Single Center Study


Affiliations
1 Clinical Pathology department, National Cancer Institute, Cairo University, Egypt
2 Medical Oncology department, National Cancer Institute, Cairo University, Egypt
3 Biostatistics and Cancer Epidemiology Department, National Cancer Institute, Cairo University, Egypt
     

   Subscribe/Renew Journal


Introduction: One of the evolving defects in acute myeloid leukemia (AML) is the BCR/ABL fusion which is the trigger of chronic myeloid leukemia (CML). Differentiating Ph +ve AML from CML in blast crisis is an ongoing challenge. In our study, we tried to differentiate between both categories and determine the prevalence of this rare entity as well as its clinical and laboratory features.

Patients and Method: We enrolled in our study 175 patients from the National Cancer Institute, Egypt; Conventional Karyotyping and qualitative RT PCR for BCR/ABL fusion proteins were done for all the patients. Positive cases were confirmed by FISH.

Results: Five/175 patients were shown to have BCR/ABL translocation with an incidence of 2.8%. Four out of the five cases were having fusion protein p210 by RT PCR, while the fifth case was having neither p210 nor p190. Most criteria of differentiation were intermingling together.

Conclusion: Further studies should be done to confirm or exclude this provisional entity. Moreover, introduction of BCR/ABL analysis in the routine may be a useful tool for introducing TKIs in these patients, which may improve the survival.


Keywords

BCR/ABL, Ph +ve AML, Qualitative RT PCR.
Subscription Login to verify subscription
User
Notifications
Font Size


Abstract Views: 508

PDF Views: 0




  • Prevalence of BCR/ABL Fusion Gene Expression in Acute Myeloid Leukemia Patients: A Single Center Study

Abstract Views: 508  |  PDF Views: 0

Authors

Lamiaa A. Fathalla
Clinical Pathology department, National Cancer Institute, Cairo University, Egypt
Naglaa M. Hassan
Clinical Pathology department, National Cancer Institute, Cairo University, Egypt
Omnia K. ElGebaly
Clinical Pathology department, National Cancer Institute, Cairo University, Egypt
Mosaad M. El Gammal
Medical Oncology department, National Cancer Institute, Cairo University, Egypt
Rasha Mahmoud Allam
Biostatistics and Cancer Epidemiology Department, National Cancer Institute, Cairo University, Egypt
Basma M. Elgamal
Clinical Pathology department, National Cancer Institute, Cairo University, Egypt

Abstract


Introduction: One of the evolving defects in acute myeloid leukemia (AML) is the BCR/ABL fusion which is the trigger of chronic myeloid leukemia (CML). Differentiating Ph +ve AML from CML in blast crisis is an ongoing challenge. In our study, we tried to differentiate between both categories and determine the prevalence of this rare entity as well as its clinical and laboratory features.

Patients and Method: We enrolled in our study 175 patients from the National Cancer Institute, Egypt; Conventional Karyotyping and qualitative RT PCR for BCR/ABL fusion proteins were done for all the patients. Positive cases were confirmed by FISH.

Results: Five/175 patients were shown to have BCR/ABL translocation with an incidence of 2.8%. Four out of the five cases were having fusion protein p210 by RT PCR, while the fifth case was having neither p210 nor p190. Most criteria of differentiation were intermingling together.

Conclusion: Further studies should be done to confirm or exclude this provisional entity. Moreover, introduction of BCR/ABL analysis in the routine may be a useful tool for introducing TKIs in these patients, which may improve the survival.


Keywords


BCR/ABL, Ph +ve AML, Qualitative RT PCR.



DOI: https://doi.org/10.37506/v10%2Fi12%2F2019%2Fijphrd%2F192424